Ann: Q3 FY23 Trading Update Presentation, page-5

Just spotted this little article about BMT.

Clearly it was a very solid update during the week - with great organic & other growth, and overheads increases significantly below revenue increases.

Would now like to see that they are constantly cash flow positive - and hopefully also getting close to a profit for the full year.

See article below:

Beamtree Holdings reports 51% revenue growth

While not a stock Morgans follows closely Wilkie said he thought Beamtree Holdings (ASX:BMT) announced a quite positive trading update for Q3 FY23 which saw its share price lift ~12% for the week.

BMT proprietary AI subscription based system called RippleDown offers decision support and data insights solutions to the healthcare industry and consists of two components including RippleDown Auditor and RippleDown Expert.

BMT reported continued revenue growth of +51% on pcp, strong organic revenue growth of 24%, and an operating profit improvement of 25% on pcp, which it put down to contract wins both in Australia and internationally.

BMT said the Abbott partnership continues to deliver to expectations with three new RippleDown licences in Q3 bringing the total to 11 new Tier 1 licences since the partnership renewal in December 2022, an increase of 40% in the current year.

Total Tier 1 licences are 38, currently generating ~$1m per million in recurring revenue.

The company said larger Abbott co-sales (Tier 2) partnership pipeline continues to grow following the first co-sale licence completed with Western Diagnostics Pathology, a Healius (ASX:HLS).

Management expects a second co-sale licence to be signed in Q4 FY23 with further wins to follow into FY24 and importantly noted as the Tier 1 renewals occur, several are expected to convert to higher value Tier 2.

“This partnership with Abbott is starting to mature and feed through some solid contracts,” Wilkie said.

“The company said they expect FY23 to deliver organic revenue growth of around 25% and operating costs to run at about 10% growth so we’ll see some operating leverage roll through.

“Management recently made some long term outlook of delivering annual recurring revenue of $60 million by 2026 so there is a pretty strong growth roadmap there.”